论文部分内容阅读
ABT-089[2-甲基-3-(2-(S)-吡咯烷基-甲氧基)吡啶]是一种强效的选择性胆碱能通道调节剂,其治疗认知障碍的作用正在研究中。然而,它在狗体内迅速消除(t12为1.7h)。因此,每日一次服用的缓释剂型具有优点。本研究的目的为探讨延长ABT-089口服释放的可行性,评价亲水和亲脂基质系统对
ABT-089 [2-Methyl-3- (2- (S) -pyrrolidinyl-methoxy) pyridine] is a potent and selective cholinergic channel modulator that treats cognitive impairment In research. However, it is rapidly eliminated in dogs (t12 is 1.7h). Therefore, the sustained-release dosage form taken once daily has the advantage. The purpose of this study was to explore the feasibility of prolonging the oral release of ABT-089 to evaluate the effects of hydrophilic and lipophilic matrix systems